In a 39-page pre-publication Federal Register notice (here) the FDA discusses the issuance of a proposed rule to determine that N-acetyl-L-cysteine (NAC) is not excluded from the dietary supplement definition in the Federal Food, Drug, and Cosmetic Act (FD&C Act). In the notice the history of this “historic” event is described in detail.

The FDA says that in the past it has refused or denied petitions and other attempts to permit the NAC to be marketed as a dietary ingredient covered under the act. While the Agency was considering certain submission, it allowed enforcement discretion for the inclusion of NAC. If the proposed rule is finalized, then as explained in the document, the current enforcement discretion will cease.

The major hurdle in the past has been that there is a statutory provision, wherein if a drug product is approved by the Agency that contains NAC prior to the first marketing of a product that would otherwise fall under the definition of a dietary ingredient, the product cannot be considered a dietary ingredient. Because FDA has approved Mucomyst (acetylcysteine) in a New Drug Application in 1963, and NAC has not been marketed as a dietary supplement prior to that approval, the ingredient could not be marked legally as a dietary supplement.

The Agency notes that “[W]e are issuing this proposed rule to establish a regulation to provide for the lawful use of certain ingredients in dietary supplements that would otherwise be excluded from the dietary supplement definition and to list NAC as the first ingredient under this new regulation, consistent with our authority in sections 201(ff)(3)(B), 301(ll)(2), and 701(a) of the FD&C Act (21 U.S.C. 321(ff)(3)(B), 331(ll)(2), and 371(a)).”The FDA goes on to say that “[A]ccordingly, if a product that is or contains NAC is labeled as a dietary supplement and otherwise meets the definition of a dietary supplement under section 201(ff) of the FD&C Act, FDA would regulate such a product as a dietary supplement”.

In the background section of the FR notice the FDA explains in detail what brought the Agency to the issuance of this proposed rule. It provides the definition of a dietary supplement and explains exactly why the FDA has repeatedly in the past denied it as a dietary supplement. FDA notes “Section 201(ff)(3)(B) of the FD&C Act (the exclusion clause) provides that a product that would otherwise meet the definition of a dietary supplement loses its status as a dietary supplement if the product includes certain articles. Specifically, the general rule of section 201(ff)(3)(B)(i) of the FD&C Act is that a dietary supplement cannot include an article that was approved as a new drug under section 505 of the FD&C Act, certified as an antibiotic under section 507 of the FD&C Act, or licensed as a biologic under section 351 of the Public Health Service Act before the article was marketed as a dietary supplement or as a food”.

The Agency further goes on to state: “The general rule of section 201(ff)(3)(B)(ii) of the FD&C is that a dietary supplement cannot include an article authorized for investigation as a new drug, antibiotic, or biological for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, unless the article was marketed as a dietary supplement or as a food before such authorization”.

However, “Section 201(ff)(3)(B) of the FD&C Act provides an exception to the general rules of sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act. Under this exception, the article is not excluded if the Secretary, in the Secretary’s discretion, has issued a regulation, after notice and comment, finding that the article would be lawful under the FD&C Act”.  It is exactly this exception the FDA is requesting in the proposed rule. The Agency notes that because this rule, if finalized, will “relieve a restriction” it could take effect less than 30 days after the publication in the Federal Register. The Agency asks for comments on the proposed effective in the proposed rule.

The FR notice is a very interesting read. As noted, this is the first time the Agency has used its rule making authority to address such an exception, and could signal a potential shift in FDA historical positions in such circumstances. If the rule is finalized, it will likely be a bellwether for future dietary supplement exceptions.